Deubiquitinases in cancer
Metrics: PDF 2405 views | HTML 2949 views | ?
Rongbin Wei1,*, Xiaodong Liu2,*, Weixin Yu3,*, Tianshu Yang1, Wenping Cai1, Junjun Liu1, Xiao Huang1, Guo-tong Xu1, Shouliang Zhao3, Jianhua Yang1, Shangfeng Liu3
1Department of Ophthalmology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, P. R. China
2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China
3Department of Stomatology, Huashan Hospital, Fudan University, Shanghai 200040, P. R. China
*These authors have contributed equally to this work
Shangfeng Liu, e-mail: firstname.lastname@example.org
Jianhua Yang, e-mail: email@example.com
Shouliang Zhao, e-mail: SLzhao@tongji.edu.cn
Keywords: deubiquitinases, cancer, ubiquitylation, inhibitor
Received: January 16, 2015 Accepted: April 24, 2015 Published: May 07, 2015
Deubiquitinases are deubiquitinating enzymes (DUBs), which remove ubiquitin from proteins, thus regulating their proteasomal degradation, localization and activity. Here, we discuss DUBs as anti-cancer drug targets.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.